NCT02096042 2023-10-10
Phase I/II - Brentuximab/5-Azacytidine in Acute Myeloid Leukemia (AML)
M.D. Anderson Cancer Center
Phase 1/2 Terminated
Clinical Trials
4 trialsNCT01830777 2020-04-14
Brentuximab Vedotin + Re-induction Chemotherapy for AML
Massachusetts General Hospital
Phase 1 Completed
NCT01700751 2019-04-16
Brentuximab Vedotin Prevention of (GVHD) After Unrelated Allogeneic Stem Cell Transplantation
Washington University School of Medicine
Phase 1 Completed
NCT01461538 2016-03-04
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Seagen Inc.
Phase 2 Completed